460 filings
Page 4 of 23
4
Mark L. Jacobson
6 Mar 23
Axsome Therapeutics / Mark L. Jacobson ownership change
6:15pm
4
Pizzie Nick
6 Mar 23
Axsome Therapeutics / Nick Pizzie ownership change
6:14pm
4
AXSM
Axsome Therapeutics Inc
6 Mar 23
Axsome Therapeutics / Hunter R. Murdock ownership change
6:14pm
4
AXSM
Axsome Therapeutics Inc
6 Mar 23
Axsome Therapeutics / Mark Coleman ownership change
6:13pm
4
Jeffs Roger
6 Mar 23
Axsome Therapeutics / ROGER JEFFS ownership change
6:13pm
4
AXSM
Axsome Therapeutics Inc
6 Mar 23
Axsome Therapeutics / Mark E Saad ownership change
6:12pm
10-K
2022 FY
AXSM
Axsome Therapeutics Inc
Annual report
27 Feb 23
5:37pm
8-K
AXSM
Axsome Therapeutics Inc
27 Feb 23
Axsome Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
7:05am
8-K
AXSM
Axsome Therapeutics Inc
22 Feb 23
Axsome Therapeutics Enters into License Agreement with Pharmanovia to Expand Commercialization and Further Develop Sunosi® (solriamfetol) in Europe
7:05am
SC 13G/A
AXSM
Axsome Therapeutics Inc
14 Feb 23
Axsome Therapeutics / Venrock Healthcare Capital Partners II ownership change
5:11pm
SC 13G/A
AXSM
Axsome Therapeutics Inc
14 Feb 23
Axsome Therapeutics / PFM Health Sciences ownership change
4:06pm
SC 13G/A
Fairmount Funds Management LLC
14 Feb 23
Axsome Therapeutics / Fairmount Funds Management ownership change
3:45pm
SC 13G
AXSM
Axsome Therapeutics Inc
14 Feb 23
Axsome Therapeutics / RTW INVESTMENTS ownership change
10:07am
8-K
AXSM
Axsome Therapeutics Inc
13 Feb 23
Other Events
6:59am
SC 13G/A
Vanguard Group Inc
9 Feb 23
Axsome Therapeutics / VANGUARD ownership change
11:07am
SC 13G/A
AXSM
Axsome Therapeutics Inc
1 Feb 23
Axsome Therapeutics / BlackRock ownership change
4:54pm
8-K
AXSM
Axsome Therapeutics Inc
9 Jan 23
Entry into a Material Definitive Agreement
7:05am
4
Coleman Mark
4 Jan 23
Axsome Therapeutics / Mark Coleman ownership change
4:11pm
S-3ASR
AXSM
Axsome Therapeutics Inc
2 Dec 22
Automatic shelf registration
5:27pm
8-K
AXSM
Axsome Therapeutics Inc
28 Nov 22
Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in the ACCORD Phase 3 Trial in Alzheimer’s Disease Agitation
7:07am